Search

Coloplast A-S (Class B)

Fermé

546.8 0.92

Résumé

Variation du prix de l'action

24h

Actuel

Min

539.6

Max

552

Chiffres clés

By Trading Economics

Revenu

70M

875M

Ventes

2M

7B

P/E

Moyenne du Secteur

33.486

90.831

BPA

3.88

Rendement du dividende

4.24

Marge bénéficiaire

12.572

Employés

16,744

EBITDA

2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.24%

2.20%

Prochains Résultats

6 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-947M

122B

Ouverture précédente

545.88

Clôture précédente

546.8

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 janv. 2026, 23:43 UTC

Market Talk

Gold Consolidates; May Face Technical Correction -- Market Talk

20 janv. 2026, 23:42 UTC

Market Talk

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 janv. 2026, 23:41 UTC

Résultats

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 janv. 2026, 23:29 UTC

Market Talk

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 janv. 2026, 23:26 UTC

Market Talk

Global Equities Roundup: Market Talk

20 janv. 2026, 23:26 UTC

Market Talk

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 janv. 2026, 22:45 UTC

Acquisitions, Fusions, Rachats

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 janv. 2026, 22:45 UTC

Acquisitions, Fusions, Rachats

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 janv. 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 janv. 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 janv. 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 janv. 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 janv. 2026, 22:27 UTC

Acquisitions, Fusions, Rachats

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 janv. 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 janv. 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 janv. 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 janv. 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 janv. 2026, 22:18 UTC

Résultats

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 janv. 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 janv. 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 janv. 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 janv. 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 janv. 2026, 22:13 UTC

Acquisitions, Fusions, Rachats

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 janv. 2026, 22:11 UTC

Acquisitions, Fusions, Rachats

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 janv. 2026, 22:10 UTC

Acquisitions, Fusions, Rachats

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 janv. 2026, 22:08 UTC

Acquisitions, Fusions, Rachats

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 janv. 2026, 22:07 UTC

Acquisitions, Fusions, Rachats

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 janv. 2026, 22:06 UTC

Résultats

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 janv. 2026, 22:00 UTC

Market Talk
Acquisitions, Fusions, Rachats

ESG Roundup: Market Talk

20 janv. 2026, 21:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat